Showing results (431-440 of 494) with videos related to

Sort By:
Pageof 50
Science Advances|March 21, 2025
Pathway-instructed therapeutic selection of ruxolitinib reduces neuroinflammation in fungal postinfectious inflammatory syndromeJessica C Hargarten, Kenneth Ssebambulidde, Seher H Anjum, et al.
Pain|May 3, 2019
Antibodies binding the head domain of P2X4 inhibit channel function and reverse neuropathic painWendy A Williams, John E Linley, Clare A Jones, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 4, 2020
Extensive sequence and structural evolution of Arginase 2 inhibitory antibodies enabled by an unbiased approach to affinity maturationDenice T Y Chan, Lesley Jenkinson, Stuart W Haynes, et al.
Biorxiv : the Preprint Server for Biology|May 4, 2026
Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancerWen-Hsuan Chang, Alec J Vaughan, Addison G Stamey, et al.
Arthritis and Rheumatism|November 13, 2003
Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulatorKevin P Baker, Bryan M Edwards, Sarah H Main, et al.
American Heart Journal|June 15, 2018
Randomized placebo controlled trial evaluating the safety and efficacy of single low-dose intracoronary insulin-like growth factor following percutaneous coronary intervention in acute myocardial infarction (RESUS-AMI)Noel M Caplice, Mary C DeVoe, Janet Choi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 25, 2016
A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn BindingJulie Douthwaite, Jacques Moisan, Cyril Privezentzev, et al.
Mabs|September 4, 2020
Structural and functional characterization of C0021158, a high-affinity monoclonal antibody that inhibits Arginase 2 function via a novel non-competitive mechanism of actionMark Austin, Daniel Burschowsky, Denice T Y Chan, et al.
Mabs|March 4, 2014
A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthmaE Suzanne Cohen, Claire L Dobson, Helena Käck, et al.
Scientific Reports|June 17, 2023
Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunctionElizabeth England, D Gareth Rees, Ian Christopher Scott, et al.
Pageof 50